ArticleAsian journal of andrology2011
Low-dose testosterone treatment decreases oxidative damage in TM3 Leydig cells.
Article in Asian journal of andrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Evaluation of anti-gonadal activity of chloroform fraction ofAvicenna journal of phytomedicine · 2026Article
- Contribution and Regulation of HIF-1α in Testicular Injury Induced by Diabetes Mellitus.Biomolecules · 2025Review
- Quantification of Pesticides and In Vitro Effects of Water-Soluble Fractions of Agricultural Soils in South Africa.Archives of environmental contamination and toxicology · 2025Article
- Review of the effect of atrazine on the HPG axes and steroidogenic pathways in males: relevance for testicular and prostate cancer.Frontiers in toxicology · 2025Review
- The Double-Edged Sword of Total Antioxidant Capacity: Clinical Significance and Personal Experience.Antioxidants (Basel, Switzerland) · 2024Review
- Could Lower Testosterone in Older Men Explain Higher COVID-19 Morbidity and Mortalities?International journal of molecular sciences · 2022Review
- The Mechanisms and Management of Age-Related Oxidative Stress in Male Hypogonadism Associated with Non-communicable Chronic Disease.Antioxidants (Basel, Switzerland) · 2021Review
- Cytotoxic Potential of Biogenic Zinc Oxide Nanoparticles Synthesized FromFrontiers in bioengineering and biotechnology · 2021Article
- Testosterone promotes GPX5 expression of goat epididymal epithelial cells cultured in vitro.In vitro cellular & developmental biology. Animal · 2019Article
- Vascular Dysfunction among Malaysian Men with Increased BMI: An Indication of Synergistic Effect of Free Testosterone and Inflammation.Medicina (Kaunas, Lithuania) · 2019Article
- Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?Neuroscience and biobehavioral reviews · 2019Review
- Clinical Significance of Low Blood Testosterone Concentration in Men as a Cardiovascular Risk Factor From the Perspective of Blood Rheology.Cardiology research · 2019Article
- Acridine orange exhibits photodamage in human bladder cancer cells under blue light exposure.Scientific reports · 2017Article
- Gentamicin Induced Nephrotoxicity: The Role of Sex Hormones in Gonadectomized Male and Female Rats.Scientifica · 2016Article
- Article
- Reactive oxygen species: players in the cardiovascular effects of testosterone.American journal of physiology. Regulatory, integrative and comparative physiology · 2016Review
- Article
- Physically active men show better semen parameters and hormone values than sedentary men.European journal of applied physiology · 2012Article
- Chronic stress induces ageing-associated degeneration in rat Leydig cells.Asian journal of andrology · 2012Article
- Testosterone and vascular function in aging.Frontiers in physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testosterone replacement therapy has benefits for aging men and those with hypogonadism. However, the effects of exogenous testosterone on Leydig cells are still unclear and need to be clarified. In this report, we demonstrate that testosterone supplementation can reduce oxidative damage in Leydig cells. The TM3 Leydig cell line was used as an in vitro cell model in this study. Cytoprotective effects were identified with 100-nmol l⁻¹ testosterone treatment, but cytotoxic effects were found with ≥ 500-nmol l⁻¹ testosterone supplementation. Significantly reduced reactive oxygen species (ROS) generation, lipid peroxide contents and hypoxia induction factor (HIF)-1α stabilization and activation were found with 100-nmol l⁻¹ testosterone treatment. There was a 1.72-fold increase in ROS generation in the 500-nmol l⁻¹ compared to the 100-nmol l⁻¹ testosterone treatment. A 1.58-fold increase in steroidogenic acute regulatory protein (StAR) expression was found in 50-nmol l⁻¹ testosterone-treated cells (P < 0.01). Chemically induced hypoxia was attenuated by testosterone supplementation. Leydig cells treated with low-dose testosterone supplementation showed cytoprotection by decreasing ROS and lipid peroxides, increasing StAR expression and relieving hypoxia stress as demonstrated by HIF-1α stabilization. Increased oxidative damage was found with ≥ 500-nmol l⁻¹ testosterone manipulation. The mechanism governing the differential dose effects of testosterone on Leydig cells needs further investigation in order to shed light on testosterone replacement therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.